Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials
Summary Endpoints
     
Demonstrated or suggested benefit Inconclusive results Uncertain results Safety results
mRNA vaccine14noneinconclusive results for: mechanical ventilation; infection (PCR positive symptomatic or not); vaccine efficacy after dose 1 (and before dose 2)

suggested 92 % decrease in confirmed Covid-19, from 1st dose but the degree if certainty is unassessable

demonstrated 84 % decrease in confirmed COVID (any severity) but the degree if certainty is unassessable

suggested 87 % decrease in hospitalization but the degree if certainty is unassessable

suggested 90 % decrease in symptomatic Covid-19 but the degree if certainty is unassessable

suggested 63 % decrease in asymptomatic COVID case but the degree if certainty is unassessable

suggested 98 % decrease in ICU admission but the degree if certainty is unassessable

suggested 91 % decrease in severe COVID-19 occurrence but the degree if certainty is unassessable

-
protein subunit vaccine1none-

suggested 82 % decrease in confirmed COVID (any severity) but the degree if certainty is unassessable

-
A EFFACER BBV152 (Bharat Biotech, India)0- - - -
A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)0- - - -
A EFFACER_ Vero cell0- - - -
A EFFACER_sequential Immunization0- - - -
BCG vaccination0- - - -
complete primary vaccine series0- - - -
CoVLP (MT-2766, Medicago)0- - - -
DNA vaccine0- - - -
ebola vaccine0- - - -
first booster dose0- - - -
heterologous prime-boost0- - - -
Inactivated virus vaccine0- - - -
Non replicating viral vector0- - - -
Replicating Viral Vector0- - - -
seasonal influenza vaccines0- - - -
second booster dose0- - - -
virus-like particles vaccine0- - - -

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons